Biotech Implosion: Allos Therapeutics (ALTH)
Allos Therapeutics, Inc. (ALTH-NASDAQ) is indicated down almost 20% in thin pre-market trading after it announced that top line results from ENRICH, the Company's pivotal Phase III study of EFAPROXYN ...Read Full Story »

